You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 3776 to 3800 of about 6010
Next 25
03/30/2008
OncoMethylome Sciences Grants Commercial License To LabCorp For MGMT Methylation Testing
Reduced Glioma Growth Following Dexamethasone or Anti-Angiopoietin 2 Treatment.
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma.
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
The harm-benefit tradeoff in "bad deal" trials.
03/27/2008
03/22/2008
Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Dan`s Fund Created at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute to support Brain Cancer Research
03/18/2008
A fatal outcome in a patient with glioblastoma multiforme after receiving high-dose methotrexate.
Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.
Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.
Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Anti-brain cancer drug has side-effect
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Doctors See How Cancer Drug Can Damage Kidneys
Signaling System May Halt Brain Cancer